Kazia Therapeutics
KZIAKazia Therapeutics Limited (ASX: KZIA) is an oncology-focused biotechnology company based in Sydney, Australia. The company's primary business is the development of novel therapies for the treatment of various cancers, with a particular emphasis on brain cancer. Its strategy involves in-licensing and developing differentiated drug candidates, advancing them through clinical trials to generate data that supports potential regulatory approval and commercialization. The company's lead asset is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway. This investigational drug is being developed for multiple forms of brain cancer, most notably glioblastoma, an aggressive and difficult-to-treat primary brain tumor. Paxalisib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for glioblastoma and has also received Fast Track Designation. Beyond paxalisib, Kazia's pipeline includes EVT801, a small molecule inhibitor of VEGFR3 that is in early-stage clinical development for advanced solid tumors. As a publicly listed entity, Kazia Therapeutics operates as a clinical-stage company, meaning its activities are centered on conducting clinical trials to evaluate the safety and efficacy of its drug candidates. The company's progress and strategy are communicated through its filings on the Australian Securities Exchange under the ticker symbol KZIA. Its work is conducted through collaborations with academic institutions and clinical research organizations within the global oncology community.
KZIA · Stock Price
Historical price data
About
Kazia Therapeutics Limited (ASX: KZIA) is an oncology-focused biotechnology company based in Sydney, Australia. The company's primary business is the development of novel therapies for the treatment of various cancers, with a particular emphasis on brain cancer. Its strategy involves in-licensing and developing differentiated drug candidates, advancing them through clinical trials to generate data that supports potential regulatory approval and commercialization. The company's lead asset is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway. This investigational drug is being developed for multiple forms of brain cancer, most notably glioblastoma, an aggressive and difficult-to-treat primary brain tumor. Paxalisib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for glioblastoma and has also received Fast Track Designation. Beyond paxalisib, Kazia's pipeline includes EVT801, a small molecule inhibitor of VEGFR3 that is in early-stage clinical development for advanced solid tumors. As a publicly listed entity, Kazia Therapeutics operates as a clinical-stage company, meaning its activities are centered on conducting clinical trials to evaluate the safety and efficacy of its drug candidates. The company's progress and strategy are communicated through its filings on the Australian Securities Exchange under the ticker symbol KZIA. Its work is conducted through collaborations with academic institutions and clinical research organizations within the global oncology community.